市场调查报告书
商品编码
1466560
胰臟癌药物市场:按类型、产品、应用分类 - 全球预测 2024-2030Pancreatic Cancer Therapeutics Market by Type (Endocrine Pancreatic Cancer, Exocrine Pancreatic Cancer), Product (Chemotherapy, Gene Therapy, Immunotherapy), End-Use - Global Forecast 2024-2030 |
※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。
胰臟癌治疗市场规模预计2023年为46.7亿美元,2024年达51.4亿美元,预计2030年将达到90.9亿美元,复合年增长率为9.95%。
胰臟癌药物包括多种用于控制和对抗胰臟癌的治疗方法,胰臟癌以其侵袭性和严峻的预后而闻名。这种恶性的治疗方法包括手术、放射线治疗、化疗、标靶治疗、免疫治疗和旨在缓解症状和改善患者生活品质的支持性治疗。由于人口老化、生活方式相关危险因子和遗传易感性等因素,胰臟癌盛行率不断上升,推动了对治疗胰臟癌药物的需求。此外,政府旨在扩大获得负担得起的胰臟癌治疗的支持性政策正在扩大患者的治疗选择范围。然而,复杂的报销情况以及临床试验无法提供有用且可靠的结果引起了人们对治疗准确性和有效性的担忧。此外,对这种疾病的生物学的理解也取得了进展,导致了标靶治疗药物和个人化医疗方法的发展。这些治疗方法旨在抑制促进胰臟癌细胞生长和转移的特定途径和机制。
主要市场统计 | |
---|---|
基准年[2023] | 46.7亿美元 |
预测年份 [2024] | 51.4亿美元 |
预测年份 [2030] | 90.9亿美元 |
复合年增长率(%) | 9.95% |
外分泌型胰臟癌的快速进展需要快速开发治疗方案
胰臟神经内分泌肿瘤(NET),也称为内分泌胰臟癌或胰岛细胞肿瘤,是一种涉及胰臟中称为胰岛细胞的内分泌细胞快速异常生长的癌症。此类癌症的治疗通常涉及手术切除癌细胞或胰臟的主要部分和尾部。此外,对于无法透过手术切除的肿瘤,可以采用化疗和荷尔蒙疗法的组合。外分泌胰臟癌(腺癌)是在携带胰液并帮助消化的导管内的胰臟组织中形成的癌症。然而,外分泌胰臟癌比内分泌胰臟癌进展得更快。
产品扩大了核准的化疗方案的数量
化疗涉及全身施用抑制癌细胞生长的药物,仍是胰臟癌治疗的重要支柱。这些细胞毒性药物透过口服或註射给药,但它们会产生副作用,因为它们无法区分恶性和正常细胞。然而,化疗是治疗方法的重要组成部分,并与其他策略一起使用以改善患者预后。基因治疗是一种尖端技术,将新的遗传物质引入患者的细胞中,以纠正导致癌症生长的缺陷基因或引入引发针对癌细胞的免疫反应的基因。目前,胰臟癌的基因治疗主要是探索性的,仅限于临床研究。免疫疗法是一个快速发展的领域,利用人体的免疫防御来对抗癌症。胰臟癌治疗,包括查核点抑制剂、治疗性疫苗和过继性细胞疗法,因其有效靶向癌细胞的能力而受到密切关注。免疫疗法治疗胰臟癌的效果各不相同。然而,正在进行的研究正在评估其潜力,特别是对于具有某些遗传标记的患者。放射线治疗是一种使用高能量粒子消灭癌细胞的技术,可作为单一治疗方法或与外科手术联合治疗胰臟癌。立体定位放射治疗 (SBRT) 等技术进步提高了放射治疗的精确度,并最大限度地减少了对健康组织的附带损害。对于早期胰臟癌,完全切除肿瘤的手术是首选方法。各种手术技术,例如惠普尔手术和远端切除术,是由肿瘤的胰臟位置决定的。手术的可用性取决于癌症的阶段和患者的健康状况,化疗和放射线治疗通常结合使用以优化结果。标靶治疗透过精确抑制特定的分子异常或参与肿瘤进展的途径,对癌症提供更微妙的攻击。
最终用途:扩大胰臟癌治疗研究机构的合作研究和研究计划
该诊所提供个人化医疗,重点在于化疗和患者追踪。然而,医院提供先进的手术技术和术后护理设施,使其成为为胰臟癌患者提供全面护理的核心。医院对于进行惠普尔手术等大型手术至关重要,这对于治疗可手术的胰臟癌至关重要。研究和学术机构正在与生物製药公司合作开发和测试新的治疗方法。此外,它为实证实践奠定了基础,有助于全面了解疾病管理,从而改善药物和护理策略。
区域洞察
美洲地区,特别是美国和加拿大,具有强大的临床管线、高医疗保健支出以及多家大型製药公司的存在。美国食品药物管理局(FDA) 已向多种胰臟癌药物核准快速通道、突破性疗法和孤儿药资格,加快了监管核准流程。德国、法国、英国等欧洲国家医疗费用高、医疗设施先进、报销政策优惠。欧洲药品管理局 (EMA) 在核准新治疗方法发挥关键作用,对市场成长产生积极影响。私营和公共机构之间的密切合作正在推动癌症治疗研究的创新。中国、日本、印度和韩国等亚太国家的患者人数不断增长,人们对癌症疾病的认识不断提高,这推动了对治疗方案的需求。印度等国家的学名药本地生产不断增加,促进了区域市场的动态。
FPNV定位矩阵
FPNV定位矩阵对于评估胰臟癌药物市场至关重要。我们检视与业务策略和产品满意度相关的关键指标,以对供应商进行全面评估。这种深入的分析使用户能够根据自己的要求做出明智的决策。根据评估,供应商被分为四个成功程度不同的像限:前沿(F)、探路者(P)、利基(N)和重要(V)。
市场占有率分析
市场占有率分析是一种综合工具,可以对胰臟癌治疗市场供应商的现状进行深入而深入的研究。全面比较和分析供应商在整体收益、基本客群和其他关键指标方面的贡献,以便更好地了解公司的绩效及其在争夺市场占有率时面临的挑战。此外,该分析还提供了对该行业竞争特征的宝贵见解,包括在研究基准年观察到的累积、分散主导地位和合併特征等因素。这种详细程度的提高使供应商能够做出更明智的决策并制定有效的策略,从而在市场上获得竞争优势。
1. 市场渗透率:提供有关主要企业所服务的市场的全面资讯。
2. 市场开拓:我们深入研究利润丰厚的新兴市场,并分析其在成熟细分市场的渗透率。
3. 市场多元化:提供有关新产品发布、开拓地区、最新发展和投资的详细资讯。
4. 竞争评估和情报:对主要企业的市场占有率、策略、产品、认证、监管状况、专利状况和製造能力进行全面评估。
5. 产品开发与创新:提供对未来技术、研发活动和突破性产品开发的见解。
1.胰臟癌治疗药物市场规模及预测如何?
2.胰臟癌治疗药物市场预测期内需要考虑投资的产品、细分市场、应用和领域有哪些?
3.胰臟癌治疗药物市场的技术趋势和法规结构是什么?
4.胰臟癌治疗药物市场主要厂商的市场占有率如何?
5.进入胰臟癌药物市场合适的型态和策略手段是什么?
[198 Pages Report] The Pancreatic Cancer Therapeutics Market size was estimated at USD 4.67 billion in 2023 and expected to reach USD 5.14 billion in 2024, at a CAGR 9.95% to reach USD 9.09 billion by 2030.
Pancreatic cancer therapeutics encompass a variety of treatment modalities used to manage and combat pancreatic cancer, known for its aggressive nature and challenging prognosis. The therapeutic landscape for this malignancy includes surgery, radiation therapy, chemotherapy, targeted therapy, immunotherapy, and supportive care measures that aim to relieve symptoms and improve the quality of life for patients. The need for pancreatic cancer therapeutics is driven by the increasing prevalence of the disease, attributed to factors such as aging populations, lifestyle-related risk factors, and genetic predispositions. Additionally, supportive government policies to expand access to affordable pancreatic cancer treatment have extended the scope and reach of the therapeutic options for patients. However, the complex reimbursement landscape and the inability of clinical trials to provide beneficial and credible results pose concerns about the accuracy and efficacy of the therapies. Moreover, there has been some significant progress in understanding the biology of the disease, resulting in the development of targeted therapeutics and personalized medicine approaches. These treatments are designed to interfere with specific pathways or mechanisms that promote the growth and spread of pancreatic cancer cells.
KEY MARKET STATISTICS | |
---|---|
Base Year [2023] | USD 4.67 billion |
Estimated Year [2024] | USD 5.14 billion |
Forecast Year [2030] | USD 9.09 billion |
CAGR (%) | 9.95% |
Type: Need for rapid deployment of therapeutic options due to fast progression of exocrine pancreatic cancer
Pancreatic neuroendocrine tumors (NETs), also called endocrine pancreatic cancer or islet cell tumors, are a type of cancer associated with the rapid and abnormal growth of endocrine cells, called islet cells, in the pancreas. Treatment for this type of cancer usually involves surgery to remove the tumor cells or the major parts of the body and tail of the pancreas. Furthermore, for tumors that cannot be removed by surgery, treatment may include a combination of chemotherapy or hormone therapy. Exocrine pancreatic cancer, or adenocarcinoma, refers to cancers that form in the tissue of the pancreas, within the ducts that carry pancreatic juices and aid digestion. However, compared to endocrine pancreatic cancers, exocrine pancreatic cancers advance rapidly.
Product: Expanding number of approvals for chemotherapy treatment options
Chemotherapy remains an essential pillar in the treatment of pancreatic cancer, involving systemic drug administration to impede cancer cell proliferation. These cytotoxic medications can be taken orally or injected, and their inability to distinguish between malignant and normal cells results in side effects. However, chemotherapy is a critical component of the therapeutic regimen, employed alongside other strategies to enhance patient outcomes. Gene therapy represents a cutting-edge technique, delivering new genetic material into patients' cells to rectify defective genes responsible for cancer growth or to introduce genes that trigger an immune response against tumor cells. Presently, gene therapy for pancreatic cancer is largely exploratory and confined to clinical research, holding the promise of more precise, individualized treatments in the future. Immunotherapy is a rapidly evolving field that leverages the body's immune defenses against cancer. Pancreatic cancer treatments, including checkpoint inhibitors, therapeutic vaccines, and adoptive cell therapies, are scrutinized for their ability to target cancer cells effectively. The efficacy of immunotherapy in pancreatic cancer varies. However, ongoing investigations are assessing its potential, especially for patients with specific genetic markers. Radiation therapy, a technique employing high-energy particles to eradicate cancer cells, can serve as a solitary treatment or in combination with surgical interventions to manage pancreatic cancer. Technological advancements such as stereotactic body radiation therapy (SBRT) enhance the accuracy of radiation delivery, minimizing collateral damage to healthy tissues. Surgery is the preferred approach for early-stage pancreatic cancer, aiming to excise the tumor completely. Various surgical techniques, such as the Whipple procedure or distal pancreatectomy, are determined by the tumor's pancreatic location. The viability of surgery depends on the cancer's stage and the patient's health status, and it is typically augmented by chemotherapy and radiation to optimize results. Targeted therapy offers a more nuanced attack on cancer by pinpointing and inhibiting specific molecular abnormalities or pathways involved in tumor progression.
End-Use: Expanding presence of collaborations and R&D initiatives in research institutes for pancreatic cancer treatment
Clinics provide personalized care with a focus on chemotherapy and patient follow-up. However, hospitals are at the core of providing comprehensive care for pancreatic cancer patients as they provide advanced surgery procedures and post-operative care facilities. They are pivotal in conducting major surgical procedures such as Whipple procedures, which are essential for treating operable pancreatic cancer. Research and academic institutions collaborate with biopharmaceutical companies to develop and test new treatments. Furthermore, they provide a foundation for evidence-based practice and contribute to the overall understanding of disease management, which can translate into improved drugs and care strategies.
Regional Insights
The Americas region, particularly the United States and Canada, is characterized by the presence of a robust clinical pipeline, high healthcare expenditure, and several major pharmaceutical companies. Food and Drug Administration (FDA) has approved designations such as Fast Track, Breakthrough Therapy, and Orphan Drug to several pancreatic cancer drugs, which accelerates the regulatory approval process. European nations such as Germany, France, and the United Kingdom are characterized by the presence of heightened healthcare spending, advanced healthcare facilities, and favorable reimbursement policies. The European Medicines Agency (EMA) plays a pivotal role in endorsing new therapeutic options, positively impacting market growth. Strong research collaborations between private and public entities drive innovation in cancer therapeutic research. In APAC countries such as China, Japan, India, and South Korea, there is a growing patient population and increasing awareness regarding cancer diseases, driving the need for therapeutic options. The increase in local generic drug production in countries such as India contributes to regional market dynamics.
FPNV Positioning Matrix
The FPNV Positioning Matrix is pivotal in evaluating the Pancreatic Cancer Therapeutics Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).
Market Share Analysis
The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Pancreatic Cancer Therapeutics Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.
Key Company Profiles
The report delves into recent significant developments in the Pancreatic Cancer Therapeutics Market, highlighting leading vendors and their innovative profiles. These include Abbvie Inc., Amgen Inc., Ascentage Pharma Group, Astellas Pharma Inc., AstraZeneca PLC, Bristol-Myers Squibb Company, C.H. Boehringer Sohn AG & Co. KG, Carl Zeiss AG, Carrick Therapeutics Limited, Cipla Limited, Dr. Reddy's Laboratories Ltd., Eli Lilly and Company, F. Hoffmann-La Roche AG, Faeth Therapeutics, Inc., FUJIFILM Holdings Corporation, GE HealthCare Technologies, Inc., GenesisCare, GlaxoSmithKline PLC, Hetero Healthcare Limited, ImmunityBio, Inc., Innovent Biologics Inc., Johnson & Johnson Services, Inc., Lupin Limited, Merck & Co., Inc., Mitsubishi Heavy Industries, Ltd., NGM Biopharmaceuticals, Inc., NovalGen, Novartis AG, PanTher Therapeutics, Inc., Pfizer, Inc., RenovoRx, Inc., Sun Pharmaceutical Industries Ltd., Teva Pharmaceutical Industries Ltd., and Zentalis Pharmaceuticals, Inc..
Market Segmentation & Coverage
1. Market Penetration: It presents comprehensive information on the market provided by key players.
2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.
3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.
4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.
5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.
1. What is the market size and forecast of the Pancreatic Cancer Therapeutics Market?
2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Pancreatic Cancer Therapeutics Market?
3. What are the technology trends and regulatory frameworks in the Pancreatic Cancer Therapeutics Market?
4. What is the market share of the leading vendors in the Pancreatic Cancer Therapeutics Market?
5. Which modes and strategic moves are suitable for entering the Pancreatic Cancer Therapeutics Market?